moderate - Consumables revenue (~65% of mix) exhibits defensive characteristics tied to non-discretionary hospital utilization, while capital equipment sales (~35%) are cyclical and sensitive to hospital system profitability and capital budgets. Elective procedure volumes correlate with employment levels and insurance coverage. International exposure adds sensitivity to European healthcare budgets and emerging market growth.

Rising rates create headwinds through: (1) higher cost of debt servicing on $1.2B term loan from Smiths Medical acquisition, (2) hospital system capital budget constraints as financing costs increase for equipment purchases, (3) valuation multiple compression for med-tech stocks as discount rates rise. Current 0.64x debt/equity manageable but interest expense material at current SOFR levels. Rate cuts would benefit capital equipment demand and reduce financing burden.

value - Stock trades at 1.6x P/S and 1.8x P/B with depressed margins, attracting investors betting on operational turnaround and margin recovery to historical 10%+ operating margins. Recent 24% six-month rally suggests momentum emerging as integration progresses. Not a growth story given 5.4% revenue growth and mature market dynamics. Minimal dividend (FCF prioritized for debt paydown), so not income-focused.